What tirzepatide clinical trial results actually tell you — and what to do with that information

What the weight-loss figures mean in practice, and why dose matters

The headline number from SURMOUNT-1 is genuinely striking: roughly one in five kilograms gone, on average, at the top dose over 72 weeks. But the trials also show something prescribers consider carefully: results scale with dose. Participants on 5mg lost less than those on 10mg, and those on 10mg lost less than those on 15mg. This dose-response pattern is why treatment starts low (at 2.5mg, a dose whose job is to help your body adjust rather than drive weight loss) and is titrated upward by a prescriber in step-wise increments.

It is also worth reading the figures for what they are: trial averages across a diverse population. Some participants lost considerably more than 20%; others lost less. Factors including starting weight, individual metabolic response, diet and activity level all influence outcomes. The trial data gives you a credible, peer-reviewed range to benchmark against, not a personal guarantee. Our Mounjaro overview covers the full picture of how the medicine works alongside lifestyle changes.

One thing the data does settle: tirzepatide's mechanism (acting on both GIP and GLP-1 receptors) produces a different appetite and metabolic response than GLP-1-only medicines. NICE's appraisal noted that indirect comparisons favour tirzepatide, and the SURMOUNT-5 head-to-head results confirmed this in a direct randomised comparison.

How NICE assessed the evidence, and what that means for UK access

Trial data becomes clinically actionable when a regulator or health technology body evaluates it. NICE's technology appraisal TA1026, published in December 2024, concluded that tirzepatide is recommended for adults with a BMI of 35 or above alongside at least one weight-related condition. Thresholds are applied 2.5 kg/m² lower for people from certain ethnic backgrounds. If less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment is subject to clinical review.

What this means practically: NHS access is phased and criteria are strict. The current rollout, which expanded to include adults with a BMI between 35 and 39.9 and four or more qualifying conditions from June 2026, means many people who could benefit are either outside the thresholds or facing a wait. Private prescribing through a regulated pharmacy is the alternative route, one that follows the same licensed eligibility criteria from the SmPC (broadly, adults with a BMI of 30 or above, or 27 or above with a weight-related condition) but does not require a GP referral or a spot on a waiting list.

If you are exploring what a private tirzepatide clinic involves, the consultation process is the starting point: eligibility is always confirmed by a prescriber, not by a trial result alone.

The decision the trial results can (and cannot) make for you

The evidence can tell you that tirzepatide is, on current data, the most effective licensed weight-management medicine available in the UK. It cannot tell you whether you are a suitable candidate, how you will respond, or whether the benefit outweighs your individual risks. That requires a clinical assessment.

A question our prescribers are asked most weeks: "If the results are that good, why do I need to see a prescriber?" Because prescription-only status exists precisely because powerful medicines need personalised oversight. Contraindications, concomitant medications, medical history and current health markers all shape whether tirzepatide is appropriate for any individual. If you are wondering whether joining a tirzepatide clinical trial near you might be another way to access the medicine and contribute to ongoing research, that is worth exploring before settling on a route. The trial populations excluded people with certain conditions; the real world is messier.

For context on what private treatment costs and what a legitimate prescription price includes, our guide to Mounjaro pricing in the UK sets out the honest picture. And if you want to understand how Eli Lilly's wider clinical programme extends beyond the weight-management trials into diabetes and cardiovascular research, that context is worth reading before your consultation too.

When you are ready to find out whether the evidence translates into a treatment plan for you, a free consultation with our prescribers is where that conversation starts.